Article

Experiences with the eco-Y-Stent® in 37 patients with tracheobronchial stenosis or esophago-tracheobronchial fistulas

Authors:
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

For tumorstenosis and fistulas near the bifurcation Y-stents are needed. The eco-YStent ® is the first selfexpanding Y-Stent made of metal. In the last 3 years till May 2009 we implanted these stents in 37 patients in our clinic, which is approximately 40% of all the stents, implanted in this period of time. Indications were malignant tumors in 34 cases, including 17 lung cancers and 14 esophageal cancers. In 3 cases the indication was a benign lesion. 12 patients had esophago-respiratory fistulas. The implantation was done in general anaesthesia with a rigid bronchoscope under X-ray control and was easily done in most patients. When needed, the stent could be combined with another selfexpandible stent. Fistula symptoms were resolved immediately. In some cases the obstruction of the stent was a problem. In those patients numerous bronchoscopies for cleaning the stent had to be done and in 3 cases the stent had to be removed, which was done without difficulty. The stent is very valuable and especially useful for the stenting very far progressed lesions.

No full-text available

Request Full-text Paper PDF

To read the full-text of this research,
you can request a copy directly from the authors.

... 11 An alternate option in these patients is the self-expanding metallic Y stent (Table 3). 1,4,7,[12][13][14][15] The initial attempt at improvising a bifurcation stent was described by Hauck et al 16 in 2003. The procedure involved 2 uncovered (18 mmÂ6 cm) self-expanding tracheal stents. ...
... 18 In contrast to the present study, all the 3 large series have deployed Y stent using guidewires and universally used fluoroscopy during the procedure. 1,7,13 In this study, we describe our initial experience of a locally manufactured (Ottomed) (Table 3), the stent does not require placement of guidewires with deployment using the rigid bronchoscope, as the bronchial limbs are stiffer and once pushed out of the introducer sheath separate at an angle almost equaling the angle of the tracheal carina (Fig. 3). The placement of 2 guidewires may be associated with technical difficulties. ...
Article
Full-text available
Background: Deployment of a bifurcation (Y) stent is often required in patients with airway obstruction or fistulization near the tracheal carina. Herein, we describe our experience with placement of self-expanding metallic Y stents. Methods: This was a retrospective analysis of data of consecutive subjects who underwent placement of self-expanding metallic Y stent over 2 years at 6 different centers. We describe the technique, complications, and outcomes of metallic Y stent placement at the tracheal carina. Results: Thirty-eight subjects (25 men) with a mean age of 54.8 years underwent Y stent placement. The most common underlying disease was carcinoma of the esophagus (65.8%). The most common indication for stent insertion was central airway obstruction in 30 (78.9%) subjects followed by airway-esophageal fistula. Respiratory failure was present in 17 (44.7%) subjects at admission. The Y stent was deployed using either the rigid (n=32) or the flexible (n=6) bronchoscope, and was successfully placed in 37 of the 38 (97.4%) subjects. There was rapid improvement in symptoms and subsequent resolution of respiratory failure after stent placement. There was no periprocedural mortality and few stent-related complications. On follow-up at 12 weeks, 18 patients had died due to progression of the underlying disease. Conclusion: The insertion of a metallic Y stent results in immediate palliation of malignant airway obstruction or airway fistulization near the tracheal carina with rapid improvement of symptoms.
Article
Full-text available
We describe 37 patients in whom 52 self-expandable metallic stents were successfully placed using a flexible bronchoscope. Indications for stenting were tracheobronchomalacia (n=13), neoplasia (n=20), and tracheal stenosis (n=4). Airway patency was restored in all patients. Symptoms improved in all but one patient. The median follow-up for all patients and the group of 16 patients alive has been 21 and 69.5 weeks, respectively. Complications have included granulomas and bronchitis. Migration or mucus plugging was not encountered. We conclude that metallic stents can be inserted safely using a flexible bronchoscope. At least in the short term, major complications are uncommon.
Article
Full-text available
Tracheobronchial stenting is performed increasingly often. Fluoroscopic control, which leads to significant radiation exposure for patients and staff, is recommended for the placement of metal stents. All consecutive patients referred to two airway centers in need of airway stenting who received stents (Ultraflex; Boston Scientific, Natick, MA) underwent placement using endoscopic guidance only. All data were collected in an ongoing continuous database. One hundred stents were placed in 96 patients for central airway obstruction, and the data were reviewed. Stents were placed in all locations within the central airways for a variety of indications but mainly for malignant obstruction. No complications occurred, and all stents were placed satisfactorily. At centers with dedicated airway teams, Ultraflex stents can be quickly and safely inserted without the need for fluoroscopy. This saves radiation exposure to patients and to staff and may lead to a more cost-effective procedure.
Article
Hintergrund: Tracheobronchiale Stents werden vorwiegend bei malignen und (histologisch) benignen Atemwegsstenosen eingesetzt. Weitere Indikationen bestehen in ösophagotrachealen Fisteln, Mediastinalfisteln und Tracheomalazien. Methode: Retrospektive Untersuchung (anhand von Patientenakte, Befragung der Hausärzte, in Einzelfällen Befragung von Angehörigen) von 7/1993 – 12/2006 in der Abteilung Pneumologie des Krankenhaus Heidehaus (ab 6/05 Pneumologie und internistische Intensivstation Oststadt-Heidehaus). Ergebnisse: Ergebnisse: Im Zeitraum von 13 Jahren von Juli 1993 bis Juni 2006 wurden 269 Stents (177 permanent, 92 temporär) bei 207 Patienten (1,3 Stents pro Patient) eingesetzt. Die Mehrheit der Patienten (173/207) litt an einer malignen Grunderkrankung. In etwa der Hälfte der Patienten wurden die Stents in die Trachea eingebracht. Die mediane Liegezeit der Stents betrug bei malignen Erkrankungen 116 Tage und bei benignen Erkrankungen 313 Tage. In ca. 40 % der Patienten kam es direkt oder indirekt zu mehr oder weniger ausgeprägten Komplikationen. Die Ergebnisse zeigen, wie wichtig eine kritische Indikationsstellung zur Stentimplantation ist. Wird bei benignen Erkrankungen ein Stent eingesetzt, kann dieser, sofern sich kurzfristig keine Probleme zeigen, sogar jahrelang belassen werden. Bei malignen Erkrankungen ergibt sich ein sehr unterschiedliches Bild, abhängig vom Stadium der Erkrankung – ob Erstdiagnose mit noch bestehenden Therapieoptionen – oder ein „Tumorendstadium”. Schlussfolgerung: Aus der Analyse ergeben sich einige Aspekte zur Vermeidung von Komplikationen wie strenge Indikationsstellung und Auswahl von für die jeweilige Indikation angemessenem Stentmaterial. Ein ethisches Dilemma stellen Tumorpatienten dar, da die anfängliche Verbesserung der respiratorischen Situation mit Fortschreiten des Tumors durch Komplikationen wieder zunichte gemacht wird.
Article
Airway stenting using a silicone stent has become widespread for the palliation of airway stenosis. We often encounter patients with tumors involving the carina between the bronchus to the right upper lobe and bronchus intermedius. However, there has not been ideal stenting for such cases, especially to maintain the patency of the right upper lobe bronchus. We report three cases of malignant disease inserted with a Y-stent so that the bronchial limbs of the stent saddle the involved carina between the bronchus to the right upper lobe and bronchus intermedius. The respiratory symptoms improved immediately after the procedure.
Article
The Dynamic stent, a bifurcated airway prosthesis facilitating coughing, was clinically evaluated. The stents were inserted bronchoscopically in 135 patients (84 male, 51 female, age 12-90 years, mean 59 years) suffering from compression stenoses, strictures or malacias of the central airways, or tracheo-esophageal fistulas. Extrinsic compression from malignant and semi-malignant tumors was the leading indication for stenting (47.4%), followed by esophago-airway fistulas (22.2%) and post-intubation stenoses (14%). Stent insertion turned out to be very easy and could be performed without complications. The Dynamic stent was well tolerated and gave immediate relief of dyspnea in most cases. Follow-up data, three months after the last implantation revealed that at least 24 patients were still alive with a stent in place and free of complaints. In 27 cases, the stent had been removed after response to treatment. One of these patients received a second in order to seal a fistula, two months after removal of the first one. 85 patients, 79 with malignant, 6 with non-malignant diseases had died, with a mean survival time of 123 days (0 to 611 days). Complications directly attributable to the stent were rare. Two patients who had received the stent to counteract severe tracheal compression from aortic abnormalities died from arrosion and hemoptysis. There were no other severe complications. Cephalad migration occurred in 4/136 inserted stents. The Dynamic stent can be considered feasible, effective, and comparitively safe.
Article
Recent progress on airway stents has provided sufficient airway patency for patients with airway obstruction; however, when the stenosis exists in the carinal zone, establishing an excellent airway condition is still troublesome because of the anatomic structure. We treated 15 patients with severe tracheobronchial stenosis involving a carinal bifurcation region, using several types of stenting devices (long T-tube, T-Y tube, wire reinforced Y tracheostomal tube, Freitag Dynamic stent [Karl Storz, Tuttlingen, Germany], and covered metallic stent). All patients had advanced inoperable tumors (lung cancer, n = 6; esophageal cancer, n = 3; thyroid cancer, n = 3; mediastinal tumor, n = 3). All but 2 patients had immediate relief of respiratory symptoms. One patient died of respiratory failure caused by pulmonary lymphatic spread 3 days after Dynamic stent insertion. In 1 patient with severe left main bronchial stenosis due to lung cancer, effective palliation was not achieved by insertion of a covered metallic stent because of its insufficient expansion against the stenosis. Mean survival after successful stenting was 4.3 months (range, 1 to 15 months). There were no complications directly attributable to the stents. As evidenced by the clinical effectiveness, airway stenting for inoperable tumor is valuable in such patients. Choosing a stent that will fully cover the lesion and allow sufficient tolerance against compression is important to successful stenting. Benefits such as ease of phonation and stent maintenance should also be considered.
Article
Locoregional progression of esophageal cancer can result in respiratory distress aving to tracheoesophageal (T-E) fistula or central airways stenosis. We report our experience of airway stenting in 51 patients with esophageal carcinoma involving the central airways. All data were recorded retrospectively. Fifty-one patients (44 men and seven women), with a mean age of 58.6 years, were analyzed. All had an esophageal squamous cell carcinoma. Severe respiratory impairment due to tumor invasion or to a tracheobronchial fistula (n= 14) was present in all patients. Nine of the 14 patients with fistula had dysphagia. Among the 37 patients without fistula, 19 had dysphagia. Sixty-six tracheobronchial stents were inserted in 51 patients: 65 Dumon stents and one Wallstent. Forty stents were implanted in the trachea, 16 in the left main bronchus and 10 in the right main bronchus. In 47 patients there was a significant improvement of respiratory symptoms. Esophageal intubation, carried out in nine patients, allowed eating and drinking in all cases. Mean survival was 107.7 days, with the longest follow-up 587 days. There was no difference between mean survival in the patients with fistulae (103.3+/-days) and the others (109.3+/-days). In two cases stent placement was responsible for death (massive hemoptysis and pneumonia). The main complications were migration (n=6), granuloma (n=2), pneumonia (n=2) and pneumothorax (n = 2). In 13 patients tumor progression in the airways was noted from one to 11 months after stenting, inducing a relapse of dyspnea. Complications are easily detected by the appearance of respiratory symptoms and do not necessitate systematic flexible bronchoscopy, but only preventive measures such as regular aerosol therapy, adapted respiratory physiotherapy and regular clinical follow-up.
Article
Patients with malignant esophagorespiratory fistulas have a poor prognosis. Treatment is palliative and involves restoration of the ability to ingest food and prevention of aspiration by insertion of esophageal or tracheobronchial stents. Because insertion of a single stent may be insufficient for palliation, a series of patients who underwent parallel stent insertion were studied. Thirteen patients with esophagorespiratory fistulas who required parallel stents were studied retrospectively. Palliation was evaluated by assessing dyspnea, dysphagia, and coughing associated with eating and/or drinking before and after insertion of stents. Insertion of the first stent (n = 13) resulted in complete relief of symptoms attributed to an esophagorespiratory fistula in 46% and in a reduction in symptoms in 54% of patients. The interval between insertion of the first and second stents ranged from 1 to 182 days (mean 46 days). Insertion of the second stent (n = 12) resulted in complete relief of symptoms in 42% and a reduction in symptoms in 58% of the patients. Parallel stent insertion may be indicated in patients with symptoms caused by malignant esophagorespiratory fistula.
Article
Thirty percent of patients with esophageal cancer have malignant involvement of the major airways, leading to respiratory distress and life-threatening major airway obstruction. Tracheobronchial stenting has been reported to be effective in providing sustained relief from obstruction. We conducted a chart review of all patients with advanced inoperable esophageal cancer who had malignant tracheobronchial obstruction requiring rigid bronchoscopy and airway stenting at our institution between June 1998 and July 2001. Outcome measures, which included survival, efficacy, and complications, were recorded. There were 11 patients (4 women) with a mean age of 61 years. Five patients had distant metastases at the time they underwent rigid bronchoscopy. Four patients who required mechanical ventilation for respiratory failure were successfully weaned off mechanical ventilation after the stenting procedure. All patients with dyspnea had immediate relief of respiratory symptoms, which was sustained for seven patients (64%). The mean duration of survival was 61 days. Two patients required repeat procedures, one for stent dislodgment on extubation and the other for stent migration. Stenting in patients with malignant tracheobronchial obstructions due to advanced esophageal cancer achieves immediate, dramatic, and sustainable relief in respiratory symptoms, conferring a survival benefit in patients whose conditions are otherwise deemed to be terminal.
Article
Between March 1997 and March 2004 we deployed 80 Ultraflex metallic expandable stents (Boston Scientific, Waterson, MA) in 69 patients under direct vision using rigid bronchoscopy. We report our medium- to long-term experience in patients for whom these stents were deployed. To date 15 patients have been followed for more than 1 year (median 41 months, range 12 to 83 months) after stent deployment. Indications for stenting in these patients were neoplasia (5), stricture (5), airway malacia (1), iatrogenic tracheal tear (1), and compression from an aortic aneurysm (1), a right interrupted aortic arch (1), and a right brachiocephalic artery aneurysm with tracheomalacia (1). Ten tracheal stents (9 covered, 1 uncovered) and 10 bronchial stents (8 uncovered, 2 covered) were inserted, and 5 patients received two stents. Five of these patients experienced no long-term problems. Complications included troublesome halitosis (5), which was difficult to treat despite various antibiotic regimes; granulation tissue formation above and below the stent that was successfully treated with low-power Nd:YAG laser therapy (7); and metal fatigue (1). We did not encounter stent migration. We conclude that Ultraflex expandable metallic stents have an important role in the management of selected patients with diverse endobronchial pathologies and are well tolerated in the long-term. Although associated granulation tissue can be successfully treated with Nd:YAG laser, halitosis can be a difficult problem to address.
Article
To evaluate the technical success and initial clinical safety and effectiveness of the use of a Y-shaped metallic stent for complex stenoses involving the carina. Thirty-five consecutive patients with complex tracheobronchial stenoses involving the carina were treated with an integrated self-expandable inverted Y-shaped metallic stent and delivery system. The Y-shaped metallic stents were placed in the tracheobronchial tree with fluoroscopic guidance. Technical success, clinical success, Hugh-Jones classification, and complications were assessed during follow-up. The delivery of the integrated self-expandable Y-shaped metallic stent in the carinal areas was technically successful and well-tolerated in all patients. Clinical success was achieved in 31 patients (89%) 1-7 days after stent placement; the procedure failed in four patients (11%). The improvement between pre- and postoperative Hugh-Jones classification grade was statistically significant (P<.001). During follow-up (mean follow-up, 192 days+/-169), all stenoses were resolved, and general physical examination of the 31 patents showed improvement with no obvious dyspnea or bleeding. Twenty-one patients were healthy without evidence of dyspnea, and the remaining 14 patients died (mean survival, 189 days+/-172) at the time of this report. The mean and median survival periods were 217 days+/-30 and 215 days+/-108, respectively. The mean and median stent patency periods were 216 days+/-30 and 215 days+/-119, respectively. Deployment of an integrated, self-expandable inverted Y-shaped metallic stent with the delivery system was a safe and effective procedure for the treatment of complex tracheobronchial stenoses involving the carina.